What Is The Clinical Mechanism And Rationale For Using 1064-Nm Nd:yag Lasers In The Treatment Of Psoriatic Plaques? Discover The Vascular Targeting Strategy

The rationale for using a 1064-nm Nd:YAG laser in psoriatic plaques is vascular and biomodulatory. Psoriatic plaques contain an expanded, abnormal dermal microvascular network that supports persistent inflammation and epidermal overgrowth. The 1064-nm wavelength penetrates relatively deeply, allowing appropriately delivered laser energy to heat and coagulate abnormal vessels while potentially producing low-fluence biomodulatory effects that reduce plaque induration and support clearance.

The treatment targets the vascular support system of the plaque, not merely its surface scale. Deep penetration is a major advantage of 1064-nm Nd:YAG, but meaningful plaque improvement may also depend on adequately addressing superficial dermal microvessels.

Why psoriatic plaques are a vascular target

Abnormal microvasculature sustains the plaque

Psoriasis is not only a disorder of excessive keratinocyte proliferation. The lesion is also associated with abnormal expansion and proliferation of the dermal papillary microvasculature.

These vessels help sustain the inflammatory environment and support the continued development of the thickened, erythematous plaque. This makes the microvascular network a logical therapeutic target.

Vascular injury can interrupt plaque support

When laser energy is absorbed by blood-containing vessels, it can be converted into heat. If the delivered energy is sufficient, the resulting thermal injury can cause selective vascular coagulation or ablation.

Reducing the abnormal vascular supply may weaken one of the mechanisms that perpetuates inflammation, erythema, and plaque formation.

How the 1064-nm Nd:YAG laser works

Deep dermal penetration

The 1064-nm wavelength penetrates more deeply than many shorter-wavelength laser systems. This allows energy to reach vascular structures within the dermis rather than acting primarily on the superficial scale or epidermis.

That depth is particularly relevant when psoriatic lesions contain a dense or deeper abnormal microvascular network.

Thermal photocoagulation

In vascular treatment, the laser is used to create controlled thermal damage in targeted microvessels. The objective is not indiscriminate heating of the entire plaque, but sufficient energy deposition to injure abnormal vessels while limiting damage to surrounding tissue.

The clinical result may include reduced erythema and gradual improvement in the plaque’s thickness and activity.

Low-fluence biomodulation

At lower fluences, Nd:YAG irradiation may have effects beyond direct vessel coagulation. The reference rationale describes a biomodulatory effect on cellular activity, which may help reduce induration and contribute to lesion resolution.

This mechanism should be viewed as complementary to vascular targeting, not as a replacement for it. The precise biological response depends on wavelength, fluence, pulse duration, treatment technique, and tissue characteristics.

Why depth is useful—but not sufficient

Psoriatic vessels are distributed at different depths

Although 1064-nm energy can reach deeper dermal vessels, clinically important abnormal microvasculature also exists near the superficial dermis. Supplementary evidence indicates that vessels within approximately the upper 0.5 mm of the dermis may be particularly important for plaque clearance, desquamation, and reduction in microvessel density.

Therefore, a treatment strategy focused only on deep penetration may not address all relevant vascular targets.

Treatment must balance deep and superficial effects

The rationale for 1064-nm Nd:YAG is strongest when its penetration is matched to the vascular anatomy of the lesion. The goal is to treat the relevant vascular network across its clinically important depth range, while avoiding unnecessary thermal injury.

This explains why treatment parameters and technique matter as much as the wavelength itself.

The clinical rationale for choosing 1064 nm

It reaches deeper abnormal vessels

The principal rationale is access. The 1064-nm wavelength can deliver energy into deeper dermal tissue, where abnormal psoriatic microvessels may be located.

This can be advantageous in thick, indurated plaques or lesions with a substantial dermal vascular component.

It offers a non-surface-dependent mechanism

The laser does not rely solely on removing scale or damaging the epidermal surface. Instead, it aims at a deeper pathological component that contributes to plaque persistence.

That makes the approach conceptually different from treatments directed primarily at epidermal proliferation or surface inflammation.

It may address both vascular and cellular components

The treatment rationale combines two potential effects:

Thermal vascular injury, reducing abnormal microvascular support.
Low-fluence biomodulation, potentially influencing cellular activity and plaque induration.

Together, these effects may support gradual reduction in erythema, thickness, and clinical activity.

Understanding the Trade-offs

Deep penetration can miss superficial targets

A deeper-reaching wavelength is not automatically superior for every vascular target. If superficial dermal microvessels are inadequately treated, plaque clearance and desquamation may be limited.

The practical implication is that treatment design should account for both superficial and deeper vascular components.

Thermal injury must be controlled

The same energy that coagulates abnormal vessels can also injure surrounding tissue if excessive or poorly delivered. Pain, erythema, blistering, pigmentary change, or other thermal effects are potential concerns with vascular laser treatment.

Appropriate patient selection, parameter adjustment, and cooling or other protective measures are therefore important.

Biomodulation is not identical to ablation

Low-fluence effects should not be interpreted as equivalent to direct vessel coagulation. Biomodulation is a proposed adjunctive mechanism, whereas vascular ablation depends on achieving sufficient thermal injury in the target vessels.

The two effects may coexist, but they require different treatment objectives and energy levels.

Nd:YAG therapy is not a universal psoriasis treatment

Psoriasis is a chronic immune-mediated disease, and plaques may recur even after local improvement. Laser treatment should therefore be understood as a lesion-directed option, not necessarily a substitute for systemic therapy, topical treatment, phototherapy, or management of psoriatic arthritis when those are clinically indicated.

How to Apply This to the Treatment Goal

The most appropriate rationale depends on what the treatment is intended to achieve.

If your primary focus is reducing plaque erythema and vascular support: Use the 1064-nm wavelength to selectively target abnormal dermal microvessels through controlled thermal coagulation.
If your primary focus is improving thick, indurated plaques: Leverage the wavelength’s deeper dermal penetration while considering the potential contribution of low-fluence biomodulatory effects.
If your primary focus is achieving plaque clearance and desquamation: Ensure that the treatment strategy also addresses superficial microvasculature rather than assuming deep vessel targeting alone is sufficient.
If your primary focus is treatment safety: Balance vascular injury against epidermal and surrounding-tissue protection through conservative, individualized parameters and appropriate clinical monitoring.

The central principle is to match laser depth and fluence to the vascular anatomy and biological behavior of the individual psoriatic plaque.

Summary Table:

Key Aspect	Description
Primary Target	Abnormal dermal microvasculature in psoriatic plaques
Wavelength	1064 nm, providing deep dermal penetration
Mechanism 1	Thermal photocoagulation of abnormal vessels
Mechanism 2	Low-fluence biomodulation reducing plaque induration
Advantage	Reaches deeper vascular components compared to shorter wavelengths
Limitation	May miss superficial vessels (<0.5 mm) important for clearance
Clinical Goal	Reduced erythema, thickness, and improved plaque clearance

Elevate your practice with BELIS's cutting-edge Nd:YAG systems, designed for precise vascular and biomodulatory treatment of psoriatic plaques. Our devices offer deep penetration, customizable parameters, and advanced cooling for safe, effective outcomes. As a leading supplier to clinics and premium salons, we provide professional-grade equipment and dedicated support. Contact us today to explore how BELIS can enhance your dermatological offerings and patient satisfaction. Get in touch with our experts!